In a retrospective study, 185 patients with previously untreated stage IB or IIA (International Federation of Gynecology and Obstetrics) squamous cell carcinoma of the cervix were found to have pelvic nodal metastasis at the time of Wertheim hysterectomy and bilateral pelvic lymphadenectomy. Of these patients, 103 received adjuvant whole-pelvis irradiation and 82 received no adjuvant therapy. Median dose of pelvic irradiation was 5000 cGy. Among the irradiated patients, in 75% the dose was 5000 cGy or greater. Matching irradiated and nonirradiated patients according to stage, tumor size, and number and location of positive nodes yielded 60 pairs. Mean length of follow-up was 3.9 years for the 60 irradiated patients and 5.8 years for the nonirradiated patients. Kaplan-Meier overall and cancer-specific survival estimates for the two groups were not significantly different (P > 0.30). During the follow-up period, 21 surgery-only patients and 22 patients treated with adjuvant radiotherapy had recurrence, but adjuvant radiotherapy decreased the proportion of recurrences occurring in the pelvis alone-27% compared with 67% in the surgery-only group (P = 0.01). o 1989 Academic PFS, IX.
INTRODUCTION
During the past four decades, the efficacy of radical hysterectomy and pelvic lymphadenectomy for treating patients with clinical stage TB or IIA cervical carcinoma has been demonstrated repeatedly; however, the pres- ' Presented at the annual meeting of the Society of Gynecologic Oncologists, Maui, Hawaii, February 5-9, 1989 . ' Current address: Department of Obstetrics and Gynecology, University of California, 1621 Alhambra Boulevard, No. 2500, Sacramento, CA 95816. To whom reprint requests should be addressed. ' Current address: 3555 Olentangy River Road, Suite 2080, Columbus, OH 43214. ence of surgically detected pelvic node metastasis has been correlated with moderately high treatment failure rates [l-3] . Because the salvage rate associated with recurrence is poor [4] , several adjuvant therapeutic approaches have been proposed in an attempt to decrease recurrences and thus increase patient survival. An example of such therapy has been the sporadic use of postoperative adjuvant pelvic irradiation with the intent of affording these patients a more favorable prognosis.
Using a matched-pairs study design, the authors summarize the pooled experiences from three institutions in an attempt to assess the benefit derived from adjuvant pelvic irradiation after Wertheim hysterectomy for earlystage squamous cell carcinoma of the cervix with pelvic nodal metastasis.
MATERIALS AND METHODS
The medical records of all patients treated by Wertheim hysterectomy and pelvic lymphadenectomy for clinical stage IB or IIA (International Federation of Gynecology and Obstetrics) carcinoma of the cervix between 1947 and 1986 were reviewed at each institution. Those patients with squamous cell carcinoma metastatic to pelvic lymph nodes were identified and their records were abstracted in detail, examining various surgical and pathologic features, specifics of postoperative pelvic irradiation, times and patterns of recurrence, and overall follow-up status. Follow-up information was obtained by correspondence, telephone, review of death certificates or some combination of these. Irradiated and nonirradiated patients were matched according to clinical stage, tumor size, and number and location of positive nodes. Overall and cancer-specific were computed for both groups and compared by using the log-rank test. Survival estimates were calculated from the date of operation. Information concerning sites of recurrence was broken down into pelvic, distant, and pelvic-plus-distant sites and compared within the two groups by the x2 test or Fisher's exact test.
RESULTS
Pelvic lymph node metastasis was detected at the time of Wertheim hysterectomy in 185 patients with clinical stage IB or IIA squamous cell carcinoma of the cervix; 95 at the Mayo Clinic, 48 at the University of Alabama, and 42 at the University of Michigan. Of these 185 patitints, 103 received adjuvant pelvic irradiation, and 82 were treated with surgery only. Matching according to clinical stage (stage IB and IIA), tumor size (largest dimension of the cervical lesion -+ 1 cm), and number (1, 2, 3, or >3) and location of positive nodes (presence or absence of common iliac nodal metastasis) produced 60 pairs (Table 1) . Paraaortic nodes were either negative or unknown, with a single exception in the surgery-only group (Table 2) .
Distribution according to surgical time intervals for each group is shown in Table 3 . The median year of treatment was 1972 for the surgery-only group and 1979 for the group receiving adjuvant irradiation. Radiation dosimetry was available for all matched patients, and patient distribution as a function of the pelvic midplane dose is given in Table 4 . The median dose of pelvic irradiation was 5000 cGY (range, 4000-6800 cGy). Of the irradiated patients, 75% received 5000 cGy or more. Median age was 42 years (range, 20-73 years) in the surgery-only group and 39 years (23-66 years) in the adjuvant treatment group.
Median duration of follow-up was 5.8 years in the surgery-only group and 3.9 years in the adjuvant irradiation group. Kaplan-Meier survival estimates for overall and cancer-specific survival were not significantly different between the two groups (Figs. 1 and 2; P > 0.30).
Absolute 5-year survival estimates for the two groups were 72 -+ 6% for surgery only and 64 + 7% for adjuvant irradiation.
During the follow-up period, 21 of the 60 surgery-only patients and 22 of the 60 patients receiving adjuvant irradiation had recurrences. The sites of initial treatment failures are presented in Table 5 . The proportion of recurrences occuring in the pelvis only was 67% in the surgery-only group and 27% in the adjuvant irradiation group (P = 0.01).
Median time to recurrence was 1.85 years for all patients, 1.4 years (range, 0.3-7.0 years) in the surgeryonly group, and 2.1 years (range, 0.4-11.8 years) in the adjuvant irradiation group. Median time to recurrence 1956-1960 1961-1965 1966-1970 1971-1975 1976-1980 1981-1986 Distribution by treatment was 0.9 year for those patients who had recurrence in pelvic and distant sites, 1.5 years for pelvic recurrence alone, and 3.0 years for distant recurrence alone.
DISCUSSION
The lack of demonstrable survival benefit from adjuvant pelvic irradiation within this population is consistent with previous reports [6-131. We attempted to eliminate a bias toward irradiating patients with more extensive disease by matching for tumor size and extent of spread.
The overall survival for both groups (5year survival of 72 and 64% for surgery only and adjuvant radiation, respectively) is slightly higher than the 50 to 60% customarily reported for node-positive patients [7-l 0,121, presumably reflecting the matching process: more patients with a small number of positive nodes were available in the surgery-only group so that a large number (36/60) of patients in each group had only one node positive. Previous work has suggested possible benefit from adjuvant irradiation for specific subsets of patients such as those with more than three positive lymph nodes [81. This study does not contain an adequate number of patients to permit meaningful evaluation of subset survivals. If the increased median follow-up time in the surgery-only group (5.8 versus 3.9 years) influenced the results, it should have accentuated any diminution in survival in that cohort. The substantial reduction in pelvic recurrence that we have observed following adjuvant pelvic irradiation is also consistent with previous studies (Table 6 ). Despite this decrease in pelvic recurrence, long-term survival was not enhanced. The previously unsubstantiated clinical observation that patients who do not have pelvic recurrence fare better in the short term is supported by our observation of a small increase in median time to recurrence, from 1.4 to 2.1 years, with the use of adjuvant irradiation. The benefit of decreased pelvic recurrence also is apparent in the doubling of median time to recurrence, from 1.5 years for pelvic failure to 3.0 years in the group with distant recurrence alone.
Statistical power remains a significant concern in this as in previous studies. With a sample size of 60 patients per group, we have a 90% chance of detecting a 30% improvement in survival at P < 0.05 and a 76% chance of detecting a 25% improvement in survival at P < 0.05, assuming a 70% 5-year survival without treatment. In summary, we have been able to confirm previous results demonstrating the absence of a discernable survival advantage with adjuvant pelvic irradiation in this setting. According to our results, if such an advantage exists it is probably no larger than 9% at 5 years (90% confidence interval, -18% to + 9%). Although we also confirmed the decrease in local recurrence after pelvic irradiation and the corresponding increase in short-term survival, the overall 5-year recurrence rates were not different. There is both sound theoretic foundation [15] and preliminary clinical evidence [16, 17] to support the contention that small volumes of squamous cell carcinoma of the cervix are potentially chemosensitive. In 8.
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